Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

FGFR2 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

FGFR2 mutation	Urothelial Cancer	FGFR2 mutation	Urothelial Cancer	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	KIN-3248 Sensitive: B - Late Trials KIN-3248 Sensitive : B	KIN-3248 Sensitive: B - Late Trials KIN-3248 Sensitive : B
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR2 mutation	Gastric Cancer	FGFR2 mutation	Gastric Cancer	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR2 mutation	Solid Tumor	FGFR2 mutation	Solid Tumor	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR2 mutation	Bladder Cancer	FGFR2 mutation	Bladder Cancer	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria ARQ 087 Sensitive : C2	ARQ 087 Sensitive: C2 – Inclusion Criteria ARQ 087 Sensitive : C2
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2	futibatinib Sensitive: C2 – Inclusion Criteria futibatinib Sensitive : C2
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	TT-00420 Sensitive: C2 – Inclusion Criteria TT-00420 Sensitive : C2	TT-00420 Sensitive: C2 – Inclusion Criteria TT-00420 Sensitive : C2
FGFR2 mutation	Solid Tumor	FGFR2 mutation	Solid Tumor	TT-00420 Sensitive: C2 – Inclusion Criteria TT-00420 Sensitive : C2	TT-00420 Sensitive: C2 – Inclusion Criteria TT-00420 Sensitive : C2
FGFR2 mutation	Non Small Cell Lung Cancer	FGFR2 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3